Biofrontera AG BFRA
Set alert
As of Apr 24, 3:47 PM ET
52-week range unavailable
- Open
- 3.10
- Prev close
- 2.67
- Mkt cap
- 75.72M
- Vol
- 4.95K
- Avg vol
- 0
- EPS
- 0.00
- P/E
- 0.00
- Div yield
- 0.00%
More statistics
- Low
- 2.60
- High
- 3.10
- Forward P/E
- -3.47
- Beta
- 1.55
- Short ratio
- 0.79
- Inst. own
- 3.00%
- Dividend
- 0.00
- Ex-div date
- Earnings
- Apr 11, 2022
- 50-d avg
- 2.89
- 200-d avg
- 4.65
- 1y target
- 8.50
2Y chart
Events in this range
- Nov 17, 2021Earnings: —; estimate 0; surprise —%
Signals (9)
| Name | Date | Ago |
|---|---|---|
| MACD: Sell Signal | Mar 4, 2022 | 4 years ago |
| MACD: Buy Signal | Mar 3, 2022 | 4 years ago |
| MACD: Sell Signal | Feb 28, 2022 | 4 years ago |
| SMA: Bearish | Feb 14, 2022 | 4 years ago |
| SMA: Bullish | Feb 9, 2022 | 4 years ago |
| MACD: Buy Signal | Jan 26, 2022 | 4 years ago |
| RSI: Oversold | Jan 24, 2022 | 4 years ago |
| MACD: Sell Signal | Jan 21, 2022 | 4 years ago |
| RSI: Oversold | Nov 23, 2021 | 4 years ago |
Key statistics
- Market cap
- 75.72M
- Enterprise value
- 66.26M
- Trailing P/E
- 0.00
- Forward P/E
- -3.47
- PEG ratio
- 0.00
- Price / sales
- 2.71
- Price / book
- 3.51
- EPS (TTM)
- -0.614
- Beta
- 1.55
- Dividend yield
- 0.00%
- Payout ratio
- 0.00%
- Profit margin
- -55.98%
- Revenue (TTM)
- 27.99M
- Revenue growth
- 14.10%
- Free cash flow
- 0
- Total cash
- 33.70M
- Total debt
- 24.24M
- Return on equity
- 0.00%
- Shares outstanding
- 28.36M
- Short % of float
- 0.00%
- 50-day average
- 2.89
- 200-day average
- 4.65
Analyst view
Consensus: buy
- Target (low)
- 8.00
- Target (mean)
- 8.50
- Target (high)
- 9.00
- Strong buy0
- Buy2
- Hold0
- Sell0
- Strong sell0
Next earnings
Apr 11, 2022
Expected Apr 11, 2022. Consensus EPS estimate -0.21.
Earnings
| Report date | Quarter ending | EPS estimate | EPS reported | Surprise | Surprise % |
|---|---|---|---|---|---|
| Apr 11, 2022 | Dec 1, 2021 | 0.00 | — | — | — |
| Nov 17, 2021 | Sep 1, 2021 | 0.00 | — | — | — |
| Aug 19, 2021 | Jun 1, 2021 | 0.00 | — | — | — |
| May 11, 2021 | Mar 1, 2021 | 0.00 | — | — | — |
| Apr 12, 2021 | Dec 1, 2020 | 0.00 | — | — | — |
| Nov 11, 2020 | Sep 1, 2020 | 0.00 | — | — | — |
Upgrades / downgrades
| Date | Firm | Action | From | To |
|---|---|---|---|---|
| Apr 20, 2020 | Benchmark | main | — | Buy |
| Nov 20, 2019 | Benchmark | main | — | Buy |
| Mar 9, 2018 | Benchmark | init | — | Speculative Buy |
About Biofrontera AG
Biofrontera AG, a biopharmaceutical company, engages in the development and commercialization of pharmaceutical products for the treatment of dermatological conditions and diseases caused primarily by exposure to sunlight that results in sun damage to the skin. Its principal product is Ameluz, a prescription drug for the treatment of lesion-directed and field-directed actinic keratosis. The company also offers BF-RhodoLED lamp, a photodynamic therapy for lesion-directed and field-directed treatment of actinic keratosis; and Belixos, an over-the-counter line of skin care cosmetic products. In addition, it is developing Ameluz for the treatment of field cancerization and nodular basal cell carcinoma. Further, the company's product portfolio includes Xepi, a prescription antibiotic cream for the treatment of impetigo; and Aktipak, a generic drug for the treatment of acne. It offers its products primarily in the United States, Europe, and Israel. The company has a collaboration and partnership agreement with Maruho Co., Ltd. Biofrontera AG was founded in 1997 and is headquartered in Leverkusen, Germany.
- Sector
- Healthcare
- Industry
- Biotechnology
- Country
- Germany
- Website
- biofrontera.com
News
- Biofrontera Inc. Reports First Quarter 2026 Financial Results and Provides a Business Update
- Biofrontera Inc. to Report First Quarter 2026 Financial Results and Host a Conference Call on May 14, 2026
- Why Is Biofrontera (BFRI) Stock Down Today?
- BFRI Stock Earnings: Biofrontera Misses EPS, Revenue Estimates
- Biofrontera AG (BFAGY) Management on Q1 2022 Results - Earnings Call Transcript
- Why Biofrontera Stock Is Surging Today
- Biofrontera Inc. (BFRI) CEO Erica Monaco on Q4 2021 Results - Earnings Call Transcript
- 5 Short Squeeze Candidates To Watch: Vinco Ventures, TSR, Biofrontera And More
- Why Are Biofrontera Shares Rising Today?
- Stocks That Hit 52-Week Lows On Tuesday
Your note
Sign in to keep a note on BFRA — it syncs with the Stock Master app.
Institution ownership
| Holder | % held | Shares | Value | Reported |
|---|---|---|---|---|
| Morgan Stanley | 0.05% | 14,900 | 44.25K | Dec 30, 2021 |
Fund ownership
| Holder | % held | Shares | Value | Reported |
|---|---|---|---|---|
| Trust For Professional Managers-PMC Diversified Equity Fund | 0.01% | 2,646 | 7.86K | Dec 30, 2021 |